Breast cancer patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) (Figure 3A) and overall survival (P = 0.040) than those with lower levels (Figure 3B). Here, KRT19 is linked to breast carcinoma.